Clozapine versus placebo in Huntington's disease: A double blind randomised comparative study

Journal of Neurology Neurosurgery and Psychiatry

Volumn 63, Issue 1, 1997, Pages 35-39

  Van Vugt, J P P ^a   Siesling, S ^a   Vergeer, M ^a   Van Der Velde, E A ^a   Roos, R A C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clozapine; Huntington's disease; Neuroleptic treatment

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; PIMOZIDE; PIPAMPERONE; SULPIRIDE; TIAPRIDE; ZUCLOPENTHIXOL;

ADULT; AGED; ANTICHOLINERGIC EFFECT; ARTICLE; CHOREA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DYSKINESIA; FATIGUE; FEMALE; HUMAN; HUNTINGTON CHOREA; HYPERSALIVATION; LIVER TOXICITY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEIZURE; TREATMENT OUTCOME; VERTIGO; VIDEORECORDING;

EID: 0030790234     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.63.1.35     Document Type: Article

References (30)

1. Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. J Neurol Neurosurg Psychiatry 1984;47:844-7.
2. Girotti F, Carella F, Scigliano G, et al. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease. J Neurol Neurosurg Psychiatry 1984;47:848-52.
3. Deroover J, Baro F, Bourguignon RP, Smets P. Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea. Curr Med Res Opin 1984; 9:329-38.
4. Feigin A, Kieburtz K, Bordwell K, et al. Functional decline in Huntington's disease. Mov Disord 1995;10:211-4.
5. Shoulson I. Huntington's disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 1981;31:1333-5.
6. Shoulson I. Care of patients and families with Huntington's disease. In: Marsden CD, Fahn S, eds. Movement disorders. London: Buttersworth, 1982:277-90.
7. Klockgether T, Dichgans J. Do neuroleptic drugs still have a place in neurological therapy? J Neurol 1990;237:221-5.
8. Schott K, Ried S, Stevens I, Dichgans J. Neuroleptically induced dystonia in Huntington's disease: a case report. Eur Neurol 1989;29:39-40.
9. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988;45:789-96.
10. Baldessarini RJ, Frankenburg FR. Clozapine - a novel antipsychotic agent. N Engl J Med 1991;324:746-54.
11. Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979;136:317-20.
12. Bonuccelli U, Ceravolo R, Maremmani C, Nuti A, Rossi G, Muratorio A. Clozapine in Huntington's chorea. Neurology 1994;44:821-3.
13. Sajatovic M, Verbanac P, Ramirez LF, Meltzer HY. Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea. Neurology 1991;41:156.
14. Colosimo C, Cassetta E, Bentivoglio AR, Albanese A. Clozapine in Huntington's disease [letter]. Neurology 1995; 45:1023-4.
15. AIMS. In: Guy W, ed. ECDEU assessment manual. RockvilIe, Maryland: US Department of Health, Education and Welfare 1976:534-7.
16. Huntington Study Group. The unified Huntington's disease rating scale: reliability and consistency. Mov Disord 1996;11:136-42.
17. Brown RG, MacCarthy B, Jahanshahi M, Maralen CD. Accuracy of self-reported disability in patients with parkinsonism. Arch Neurol 1989;46:955-9.
18. Naber D, Holzbach R, Perro C, Hippius H. Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 1992;160(suppl 17): 54-9.
19. Jann MW, Grimsley SR, Gray EC, Chang W. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993;24:161-76.
20. Penney JB, Young AB. Striatal inhomogeneities and basal ganglia function. Mov Disord 1986;1:3-15.
21. Albin RL, Reiner A, Anderson KD, Penney JB, Young AB. Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia. Ann Neurol 1990;27:357-65.
22. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990;13:266-71.
23. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-32.
24. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington's disease. Proc Natl Acad Sci USA 1988;85:5733-7.
25. Crossman AR. Neural mechanisms in disorders of movement. Comp Biochem Physiol 1989;93A:141-9.
26. Storey E, Beal MF. Neurochemical substrates of rigidity and chorea in Huntington's disease. Brain 1993;116:1201-22.
27. Sedvall G. PET imaging of dopamine receptors in human basal ganglia: relevance to mental illness. Trends Neurosci 1990;13:302-8.
28. Farde L, Nordström A-L. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry 1992;160(suppl 17):30-3.
29. Seeman P, Van Tol HHM. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994;15:264-70.
30. Klawans HL. Chorea. Can J Neurol Sci 1987;14:536-40.